Insulin-like growth factor-1 receptor (IGF-1R) as a biomarker for resistance to the tyrosine kinase inhibitor gefitinib in non-small cell lung cancer.
about
Implications of Insulin-like Growth Factor 1 Receptor Activation in Lung CancerNon-Invasive Methods to Monitor Mechanisms of Resistance to Tyrosine Kinase Inhibitors in Non-Small-Cell Lung Cancer: Where Do We Stand?CIViC databaseEGFR-TKI resistance in NSCLC patients: mechanisms and strategiesA Cell-Based Assay for Measuring Endogenous BcrAbl Kinase Activity and Inhibitor ResistanceIntegrated immunoisolation and protein analysis of circulating exosomes using microfluidic technology.Insulin-like growth factor receptor 1 (IGF1R) expression and survival in non-small cell lung cancer patients: a meta-analysis.Insulin-like growth factor (IGF) signaling in tumorigenesis and the development of cancer drug resistance.Next-Generation Covalent Irreversible Kinase Inhibitors in NSCLC: Focus on AfatinibBMS-754807 is cytotoxic to non-small cell lung cancer cells and enhances the effects of platinum chemotherapeutics in the human lung cancer cell line A549.Mechanisms of resistance to EGFR tyrosine kinase inhibitors.Bayesian model of signal rewiring reveals mechanisms of gene dysregulation in acquired drug resistance in breast cancerNovel C6-substituted 1,3,4-oxadiazinones as potential anti-cancer agents.Implication of epithelial-mesenchymal transition in IGF1R-induced resistance to EGFR-TKIs in advanced non-small cell lung cancer.Drug Resistance to EGFR Inhibitors in Lung CancermiR-223 enhances the sensitivity of non-small cell lung cancer cells to erlotinib by targeting the insulin-like growth factor-1 receptor.IGF1 Receptor Targeted Theranostic Nanoparticles for Targeted and Image-Guided Therapy of Pancreatic CancerZNF32 contributes to the induction of multidrug resistance by regulating TGF-β receptor 2 signaling in lung adenocarcinoma.IGF1R depletion facilitates MET-amplification as mechanism of acquired resistance to erlotinib in HCC827 NSCLC cells.Extracellular region of epidermal growth factor receptor: a potential target for anti-EGFR drug discovery.Current status of biomarker and targeted nanoparticle development: The precision oncology approach for pancreatic cancer therapy.Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Treatment of Metastatic Non-Small Cell Lung Cancer, with a Focus on AfatinibIdentification of microRNAs involved in gefitinib resistance of non-small-cell lung cancer through the insulin-like growth factor receptor 1 signaling pathwayMiR-30a-5p Overexpression May Overcome EGFR-Inhibitor Resistance through Regulating PI3K/AKT Signaling Pathway in Non-small Cell Lung Cancer Cell Lines.Clinical strategies for acquired epidermal growth factor receptor tyrosine kinase inhibitor resistance in non-small-cell lung cancer patients.IGF-1 receptor targeted nanoparticles for image-guided therapy of stroma-rich and drug resistant human cancer.Squamous cell transformation and EGFR T790M mutation as acquired resistance mechanisms in a patient with lung adenocarcinoma treated with a tyrosine kinase inhibitor: A case report.Suppressor of cytokine signalling-2 limits IGF1R-mediated regulation of epithelial-mesenchymal transition in lung adenocarcinoma.MiR-30a-5p confers cisplatin resistance by regulating IGF1R expression in melanoma cells.Short hairpin RNA-mediated down-regulation of CENP-A attenuates the aggressive phenotype of lung adenocarcinoma cells.Anti-proliferative, apoptotic and signal transduction effects of hesperidin in non-small cell lung cancer cells.Epidermal growth factor receptor mutations in East European non-small cell lung cancer patients.Cross-resistance to clinically used tyrosine kinase inhibitors sunitinib, sorafenib and pazopanib.Gefitinib induces cytoplasmic translocation of the CDK inhibitor p27 and its binding to a cleaved intermediate of caspase 8 in non-small cell lung cancer cells.
P2860
Q26740210-2581AED1-3FEE-4960-8362-1C94F684B258Q26741814-984E01E0-9B73-4725-96DF-B06E6297D639Q27612411-260E91F7-8153-450F-9882-A077286DE7C3Q28394310-2F040BD4-F893-48B2-BAF1-45CB1DBD4766Q28553892-CA748BEE-189B-4578-A993-8AFC1B0034A2Q34165070-6D30041F-F3D9-4670-B181-1449D016F469Q34501591-CA49EB3C-E884-48B4-A27A-D32B6A63521CQ35606589-4E939066-B37A-4639-A856-746531A8BCD9Q35807946-439ABB27-405F-42B9-9421-B9DA4254F528Q35940305-4B3EC568-BF52-4691-953E-F91514CC1829Q36238664-3ED4FE9A-0DFD-47E7-AD55-9FEF9BB72908Q36306149-C82CE19C-1094-4017-86C1-C448031FC303Q36562098-995E8130-4745-43A1-839F-6433A56C45FFQ36688968-525C701A-D1E4-4620-8C72-A75CDFF0C219Q36834883-9C279FC5-93AE-4822-8808-7712994B2629Q36983803-E6838CDD-B9A8-4676-A5F1-E026FA57E3C0Q37007341-6C963AD5-1773-4DE7-9158-96B40AA2085EQ37465944-67AA7FF1-2064-4820-9DFF-424CDAD81FFBQ38707122-2BC4A4C6-D2FB-44B2-8C3B-0FA450E102ADQ38989275-D240F04C-A3F1-4091-A2EB-BECAB0E44146Q39028976-A14F284E-4B70-4FC0-883B-65998D1374A2Q39339545-B07A7F70-F7F3-4898-B047-684CD799E760Q41623567-E5FD225D-0521-4EDE-BDFF-FA3DC8B3FE5AQ42090153-AF6362CB-0696-4CE1-B552-C37958C19613Q42279529-092D5F1A-0BDC-4D4F-AAD4-0325A00A8D26Q42576914-CF7C47EE-8B79-4872-B820-B8DF9CA28D8FQ47130691-5574EBA7-C132-4AB6-B845-1E50EC920D88Q52646119-856FD810-6AD7-4EDB-A61A-99EFC1616120Q52720005-A43530DA-DBC8-44A4-A3AC-3125FF38E655Q53019370-10E75EEA-36A9-42A8-990A-51C356ADCF93Q53548136-356ED854-D5DF-4814-A653-4FC1584CD27FQ54179471-1350619B-507D-4302-9F6B-177DB92E0A22Q54291692-382DEAEA-097A-420C-A240-684EFA0C2B8BQ54321696-A57F15C5-C094-4F6D-A4FC-DF88D7253206
P2860
Insulin-like growth factor-1 receptor (IGF-1R) as a biomarker for resistance to the tyrosine kinase inhibitor gefitinib in non-small cell lung cancer.
description
2013 nî lūn-bûn
@nan
2013 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2013 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
name
Insulin-like growth factor-1 r ...... in non-small cell lung cancer.
@ast
Insulin-like growth factor-1 r ...... in non-small cell lung cancer.
@en
Insulin-like growth factor-1 r ...... in non-small cell lung cancer.
@nl
type
label
Insulin-like growth factor-1 r ...... in non-small cell lung cancer.
@ast
Insulin-like growth factor-1 r ...... in non-small cell lung cancer.
@en
Insulin-like growth factor-1 r ...... in non-small cell lung cancer.
@nl
altLabel
Insulin-like growth factor-1 r ...... in non-small cell lung cancer
@en
prefLabel
Insulin-like growth factor-1 r ...... in non-small cell lung cancer.
@ast
Insulin-like growth factor-1 r ...... in non-small cell lung cancer.
@en
Insulin-like growth factor-1 r ...... in non-small cell lung cancer.
@nl
P2093
P2860
P3181
P1476
Insulin-like growth factor-1 r ...... in non-small cell lung cancer.
@en
P2093
Celine Mascaux
Fred R Hirsch
Koichi Yoshida
Maya Ilouze
Murry W Wynes
Norihiko Ikeda
Ronen Brenner
Tatsuo Ohira
P2860
P304
P3181
P356
10.1007/S13402-013-0133-9
P577
2013-07-01T00:00:00Z